STAT Plus: The biotech scorecard for the third quarter: 19 stock-moving events to watch
AstraZeneca
AstraZeneca bills itself as a science-led biopharmaceutical business. The British-Swiss company develops and manufactures products for a variety of conditions, including cancer, Type 2 diabetes, and respiratory issues. AstraZeneca’s top product by revenue has been Tagrisso, a medication used to treat non-small-cell lung carcinomas.
Latest
STAT Plus: ASCO Takeaways: Winners, snoozers, the China question, and the art of cancer care
STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?
STAT Plus: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
STAT Plus: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
STAT Plus: At a flashy new research hub, AstraZeneca lays out ambitious growth goals
All Coverage
advertisement
